Closo-dodecaborate(2-) as a linker for iodination of macromolecules.: Aspects on conjugation chemistry and biodistribution

被引:34
作者
Tolmachev, V
Koziorowski, J
Sivaev, I
Lundqvist, H
Carlsson, J
Orlova, A
Gedda, L
Olsson, P
Sjöberg, S
Sundin, A
机构
[1] Univ Uppsala, Div Biomed Radiat Sci, S-75121 Uppsala, Sweden
[2] Uppsala Univ, PET Ctr, Uppsala, Sweden
[3] Uppsala Univ, Dept Organ Chem, Uppsala, Sweden
[4] AN Nesmeyanov Organoelement Cpds Inst, Moscow 117813, Russia
[5] RRC Kurchatov Inst, Moscow, Russia
[6] Paul Scherrer Inst, Inst Med Radiobiol, Villigen, Switzerland
关键词
D O I
10.1021/bc980033s
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Boron-containing compounds like closo-dodecaborate(2-) are in theory suitable for radioactive labeling with halogens. The boron-halogen bond is stronger than carbon-halogen bond and is not likely to be recognized by deiodinating enzymes in vivo. Peptides and proteins may be conjugated with various closo-dodecaborate(2-)-containing ligands, and thereafter, the conjugate can be iodinated. Since closo-dodecaborate(2-) is more avidly iodinated than tyrosine in moderately acidic media, such conjugates may be directly labeled on the boron part with radioisotopes of iodine using the standard Chloramine-T procedure. Mercapto-undecahydro-closo-dodecaborate(2-) (BSH) was reacted with the double bond of allyldextran to form a boronated dextran compound of the molecular size of about 70 kDa. This compound, in the text denoted as Dx-BS, and cesium dodecahydro-closo-dodecaborate(2-) were labeled using iodine-125. The two compounds were administered to rats in order to study their in vivo stability. The results indicate that iodinated Dx-BS is stable for about 20 h in vivo. The degradation rate, as indicated by thyroid uptake, was found low. [I-125]Iodo-closo-dodecaborate(2-), which is a possible degradation product of[I-125]DX-BS-I, was rapidly excreted in urine without significant accumulation in any organ.
引用
收藏
页码:338 / 345
页数:8
相关论文
共 64 条
[1]  
ALI SA, 1990, CANC RES S, V50, P783
[2]   BINDING OF EPIDERMAL GROWTH FACTOR-DEXTRAN CONJUGATES TO CULTURED GLIOMA-CELLS [J].
ANDERSSON, A ;
HOLMBERG, A ;
CARLSSON, J ;
CARLSSON, J ;
PONTEN, J ;
WESTERMARK, B .
INTERNATIONAL JOURNAL OF CANCER, 1991, 47 (03) :439-444
[3]  
ANDERSSON A, 1992, J NEURO-ONCOL, V14, P213
[4]   QUANTITATIVE STUDIES OF MONOCLONAL-ANTIBODY TARGETING TO DISIALOGANGLIOSIDE G(D2) IN HUMAN BRAIN-TUMORS [J].
ARBIT, E ;
CHEUNG, NKV ;
YEH, SDJ ;
DAGHIGHIAN, F ;
ZHANG, JJ ;
CORDONCARDO, C ;
PENTLOW, K ;
CANETE, A ;
FINN, R ;
LARSON, SM .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1995, 22 (05) :419-426
[5]   Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations [J].
Behr, TM ;
Goldenberg, DM ;
Becker, W .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (02) :201-212
[6]  
Bernard BF, 1997, J NUCL MED, V38, P1929
[7]  
BISCHOFDELALOYE A, 1989, J NUCL MED, V30, P1646
[8]  
BISCHOFDELALOYE A, 1997, J NUCL MED, V38, P847
[9]   STRATEGY FOR BORON NEUTRON-CAPTURE THERAPY AGAINST TUMOR-CELLS WITH OVER-EXPRESSION OF THE EPIDERMAL GROWTH FACTOR-RECEPTOR [J].
CARLSSON, J ;
GEDDA, L ;
GRONVIK, C ;
HARTMAN, T ;
LINDSTROM, A ;
LINDSTROM, P ;
LUNDQVIST, H ;
LOVQVIST, A ;
MALMQVIST, J ;
OLSSON, P ;
ESSAND, M ;
PONTEN, J ;
SJOBERG, S ;
WESTERMARK, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (01) :105-115
[10]  
Carnochan P, 1994, J Nucl Biol Med, V38, P96